Inovio Pharmaceuticals Inc. (INO) stock surged by 1.26% at the last trading close as well as the INO stock price continued to rise by 5.00% in the current market session. INOVIO is a biotechnology company focusing on developing and commercializing precision-designed DNA drugs to cure and prevent infectious diseases, cancer, and HPV-related diseases. INOVIO is the first and only organization to show that a DNA drug can be administered directly into body cells using a patented smart interface, resulting in a powerful and tolerable immune response.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
What is happening?
INO announced that the findings of a study focusing on the human immune responses caused by INOVIO’s COVID-19 DNA vaccine candidate, INO-4800, against variants of concern have been released. INO-4800 induced a vigorous T cell response against all spike protein variants studied, which INO believes would be essential in providing defense against SARS-CoV-2 variants, as well as providing comparable levels of neutralizing action against both the UK and Brazilian variants as the original strain. INO-4800 is a DNA plasmid that is injected directly into body cells through a patented smart interface, resulting in a robust and tolerable immune response.
Clinical samples were taken from participants in INOVIO’s Phase 1 US-based INO-4800 clinical trial at various timepoints after vaccination. Antibodies with neutralizing action against the spike protein variants B.1.1.7 (UK variant), B.1.351 (South African variant), and P.1 were assessed (Brazilian variant). When compared to T cell responses to the initial Wuhan strain, the study found that T cell responses induced by INO-4800 vaccination were entirely preserved against the UK, South African, and Brazilian strains.
Regarding INO-4800 development Dr. Kim said, INO intends to announce Phase 2 results in the second quarter of this year, and with FDA approval, they hope to step into Phase 3 in the second quarter of this year. The predicted safety profile of INO’s COVID vaccine, as well as its durability at room temperature for more than a year and possible ability to safely improve several times, places INOVIO’s COVID-19 vaccine as a critical component in combating the virus in both pandemic and infectious nations.